EQRx Partners With Two Payers to Reduce Drug Costs, Seeks Chinese Approval of Low Cost Oncology Drugs

EQRx has formed partnerships with two healthcare insurance companies to reach its ambitious goal of reducing drug costs. The company has also sought approval for two cost-effective oncology drugs used in lung cancer in China. Will these moves be enough?

“EQRx — the buzzy biotech company with a lofty mission of making far less expensive look-alike versions of blockbuster drugs — is finally starting to sign deals with insurance companies, a key step toward launching drugs that could shake up the market for medicines. But the deals are light on details, raising questions about just how meaningful that shake-up might eventually be.” Read more here.

(Source: Kate Sheridan, STAT News, 11/2/21)